A Study of LY3471851 in Participants With Psoriasis

Nektar Therapeutics

Status and phase: Completed; Phase 1

Conditions: Psoriasis

Treatments: Drug: Placebo; Drug: LY3471851

Study type: Interventional

Funder types: Industry

Identifiers

NCT04119557

J1P-MC-KFAC (Other Identifier)

17239

Details and patient eligibility

About

The main purpose of this study is to learn more about the safety of LY3471851 when given by injection just under the skin to participants with psoriasis. The study will last up to 48 weeks and may include up to 23 visits to the study center.

Enrollment: 30 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have a confirmed diagnosis of psoriasis for at least 6 months
• Have active psoriasis plaques according to study- specific criteria
• Be willing and able to undergo skin biopsies

Exclusion criteria

• Have received certain topical medications for psoriasis within 14 days prior to baseline
• Have received certain systemic medications for psoriasis within 4 weeks prior to baseline
• Have received LY3471851 previously

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

30 participants in 3 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Participants received placebo administered subcutaneously (SC) every 2 weeks for a period of 12 weeks.

Treatment:

Drug: Placebo

Cohort 1 - 10 (Microgram Per Kilogram) μg/kg LY3471851

Experimental group

Description:

Participants received 10 μg/kg of LY3471851 SC every 2 weeks for a period of 12 weeks.

Treatment:

Drug: LY3471851

Cohort 2 - 24 μg/kg LY3471851

Experimental group

Description:

Participants received 24 μg/kg of LY3471851 SC every 2 weeks for a period of 12 weeks.

Treatment:

Drug: LY3471851